The potential use of Bacillus anthracis as a bioterrorism weapon threatens the security of populations globally, requiring the immediate availability of safe, efficient and easily delivered anthrax vaccine for mass vaccination. Extensive research efforts have been directed toward the development of recombinant subunit vaccines based on protective antigen (PA), the principal virulence factor of B. anthracis. Among the emerging technologies for the production of these vaccine antigens is our launch vector-based plant transient expression system. Using this system, we have successfully engineered, expressed, purified and characterized full-length PA (pp-PA83) in Nicotiana benthamiana plants using agroinfiltration. This plant-produced antigen e...
Anthrax is a disease caused by Bacillus anthracis. The most promising approach to the development of...
We previously described the cloning and expression of the protective antigen (PA) gene of Bacillus a...
In this study, the efficacy of two experimental vaccines against Bacillus anthracis toxinaemia was e...
The currently available anthrax vaccines are limited by being incompletely characterized, potentiall...
The currently available human vaccine for anthrax, derived from the culture supernatant of Bacillus ...
Protective antigen (PA), one of the components of the anthrax toxin, is the major component of human...
Bacillus anthracis has long been considered a potential biological warfare agent, and therefore, the...
Bacillus anthracis has long been considered a potential biological warfare agent, and therefore, the...
Subunit vaccine production is typically associated with bacterial, yeast, insect or mammalian cell c...
Protective antigen (PA), one of the components of the anthrax toxin, is the major component of human...
Inhalational anthrax, a zoonotic disease caused by the inhalation of Bacillus anthracis spores, has ...
The Centers for Disease Control (CDC) lists Bacillus anthracis as a category A agent and estimates t...
The Centers for Disease Control (CDC) lists Bacillus anthracis as a category A agent and estimates t...
Anthrax is a disease caused by Bacillus anthracis. The most promising approach to the development of...
Subunit vaccine production is typically associated with bacterial, yeast, insect or mammalian cell c...
Anthrax is a disease caused by Bacillus anthracis. The most promising approach to the development of...
We previously described the cloning and expression of the protective antigen (PA) gene of Bacillus a...
In this study, the efficacy of two experimental vaccines against Bacillus anthracis toxinaemia was e...
The currently available anthrax vaccines are limited by being incompletely characterized, potentiall...
The currently available human vaccine for anthrax, derived from the culture supernatant of Bacillus ...
Protective antigen (PA), one of the components of the anthrax toxin, is the major component of human...
Bacillus anthracis has long been considered a potential biological warfare agent, and therefore, the...
Bacillus anthracis has long been considered a potential biological warfare agent, and therefore, the...
Subunit vaccine production is typically associated with bacterial, yeast, insect or mammalian cell c...
Protective antigen (PA), one of the components of the anthrax toxin, is the major component of human...
Inhalational anthrax, a zoonotic disease caused by the inhalation of Bacillus anthracis spores, has ...
The Centers for Disease Control (CDC) lists Bacillus anthracis as a category A agent and estimates t...
The Centers for Disease Control (CDC) lists Bacillus anthracis as a category A agent and estimates t...
Anthrax is a disease caused by Bacillus anthracis. The most promising approach to the development of...
Subunit vaccine production is typically associated with bacterial, yeast, insect or mammalian cell c...
Anthrax is a disease caused by Bacillus anthracis. The most promising approach to the development of...
We previously described the cloning and expression of the protective antigen (PA) gene of Bacillus a...
In this study, the efficacy of two experimental vaccines against Bacillus anthracis toxinaemia was e...